id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-348846-mfhxac5c	Coletto, Lavinia Agra	Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID‐19 days	2020-05-02		.txt	text/plain	298	24	31	key: cord-348846-mfhxac5c cord_uid: mfhxac5c Diabetes and metabolic syndrome are acknowledged as associated with PsA and psoriasis 4 ; these comorbidities in the setting of a poorly controlled disease may worsen due to inflammation itself. In conclusion, before interrupting a chronic therapy, even if patients with PsA have an increased risk of comorbidities and serious infections compared with patients with psoriasis, 7 we suggest evaluating not only the infectious profile of immunosuppressants but also the underlying inflammatory nature of psoriatic disease itself, especially if severe and/or associated with articular involvement. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts	./cache/cord-348846-mfhxac5c.txt	./txt/cord-348846-mfhxac5c.txt